Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS)

December 1, 2014 6:21 AM

2 0

(Thomson Reuters ONE via COMTEX) -- Novartis International AG / Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS) . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Basel, Dec 1, 2014 - Novartis announced today that the Phase III INFORMS study in primary progressive multiple sclerosis (PPMS) did not show a significant difference between fingolimod and placebo on a combination of disability measures. The safety results were consistent with the well-characterized...

Read more

To category page

Loading...